BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 23926209)

  • 1. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
    Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
    Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.
    Ahmed AU; Thaci B; Tobias AL; Auffinger B; Zhang L; Cheng Y; Kim CK; Yunis C; Han Y; Alexiades NG; Fan X; Aboody KS; Lesniak MS
    J Natl Cancer Inst; 2013 Jul; 105(13):968-77. PubMed ID: 23821758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy.
    Kim CK; Ahmed AU; Auffinger B; Ulasov IV; Tobias AL; Moon KS; Lesniak MS
    Mol Ther; 2013 Nov; 21(11):2063-73. PubMed ID: 23883863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
    Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
    Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.
    Ahmed AU; Thaci B; Alexiades NG; Han Y; Qian S; Liu F; Balyasnikova IV; Ulasov IY; Aboody KS; Lesniak MS
    Mol Ther; 2011 Sep; 19(9):1714-26. PubMed ID: 21629227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
    Fares J; Ahmed AU; Ulasov IV; Sonabend AM; Miska J; Lee-Chang C; Balyasnikova IV; Chandler JP; Portnow J; Tate MC; Kumthekar P; Lukas RV; Grimm SA; Adams AK; Hébert CD; Strong TV; Amidei C; Arrieta VA; Zannikou M; Horbinski C; Zhang H; Burdett KB; Curiel DT; Sachdev S; Aboody KS; Stupp R; Lesniak MS
    Lancet Oncol; 2021 Aug; 22(8):1103-1114. PubMed ID: 34214495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
    Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
    J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma.
    Spencer D; Yu D; Morshed RA; Li G; Pituch KC; Gao DX; Bertolino N; Procissi D; Lesniak MS; Balyasnikova IV
    Theranostics; 2019; 9(7):2071-2083. PubMed ID: 31037157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
    Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
    Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
    Ulasov IV; Sonabend AM; Nandi S; Khramtsov A; Han Y; Lesniak MS
    Br J Cancer; 2009 Apr; 100(7):1154-64. PubMed ID: 19277041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction.
    Morshed RA; Gutova M; Juliano J; Barish ME; Hawkins-Daarud A; Oganesyan D; Vazgen K; Yang T; Annala A; Ahmed AU; Aboody KS; Swanson KR; Moats RA; Lesniak MS
    Cancer Gene Ther; 2015 Jan; 22(1):55-61. PubMed ID: 25525033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
    Kaliberova LN; Krendelchtchikova V; Harmon DK; Stockard CR; Petersen AS; Markert JM; Gillespie GY; Grizzle WE; Buchsbaum DJ; Kaliberov SA
    Cancer Gene Ther; 2009 Oct; 16(10):794-805. PubMed ID: 19363468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy.
    Martinez-Quintanilla J; He D; Wakimoto H; Alemany R; Shah K
    Mol Ther; 2015 Jan; 23(1):108-18. PubMed ID: 25352242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
    Chastkofsky MI; Pituch KC; Katagi H; Zannikou M; Ilut L; Xiao T; Han Y; Sonabend AM; Curiel DT; Bonner ER; Nazarian J; Horbinski CM; James CD; Saratsis AM; Hashizume R; Lesniak MS; Balyasnikova IV
    Clin Cancer Res; 2021 Mar; 27(6):1766-1777. PubMed ID: 33272983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy.
    Ulasov IV; Shah N; Kaverina NV; Lee H; Lin B; Lieber A; Kadagidze ZG; Yoon JG; Schroeder B; Hothi P; Ghosh D; Baryshnikov AY; Cobbs CS
    Oncotarget; 2015 Feb; 6(6):3977-87. PubMed ID: 25738357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
    Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F
    Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
    Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
    Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.